In vitro bone lipid synthesis in air and nitrogen.

T. Dirksen

DOI: https://doi.org/10.1016/0005-2760(71)90113-5

1971-05-04

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

Amelia Morgillo,Marcello Mazzarella,Maria Francesca Randazzo,Naomi Mancino,Marialessia Talessi,Edoardo Marovino

DOI: https://doi.org/10.33425/2639-944x.1309

2023-01-31

Journal of Medical - Clinical Research & Reviews

Abstract:Introduction: Anthracyclines are among the most powerful antineoplastic drugs ever developed and, even today, they are widely used according to various association schemes in the onco-hematological field. However, cardiotoxicity remains one of the most feared and characteristic side effects, both short and long term, often causing the premature interruption of therapy or irreversible effects after their suspension. In this article, we want to explain the underlying biological mechanisms, the clinical presentation characteristics and the possible strategies to prevent it. Materials and Methods: A computerized research was carried out for the articles to be inserted through use of international databases PUBMED, RESEARCHGATE and GOOGLE SCHOLAR, by typing in keywords such as “anthracyclines cardiotoxicity” and “cardioprotection strategies for anthracycline toxicity” and related articles. Discussion and Conclusions: The toxicity of these drugs on the heart represents the limiting factor both for their indications and for the success of the therapy, sometimes being the cause of premature interruption or impossibility of use in some patients. It depends especially on the cumulative dose used in the single patient and on the pre- existing risk conditions for the development of these ADRs, both in the short and long term. However, there are strategies that can avoid or reduce the damage, both related to the formulation of the compounds and to the co- administration of other drugs.
[Cardiotoxicity of drugs used in oncology]

A Poprach,K Petráková,J Vyskocil,R Lakomý,R Nemecek,I Kocák,I Kocáková,R Vyzula

Abstract:Administration of cytotoxic drugs is accompanied by many serious side effects, with cardiac toxicity as one of the most dangerous. In clinical practice anthracyclines are the best known chemotherapeutic agents linked to cardiotoxicity, however there are a number of other anti-cancer drugs (cyclophosphamide, taxans, trastuzumab, 5-fluorouracil, imunomodulators etc) that may cause cardiac toxicity as well. Basic mechanism through which anthracylines cause cardiac damage is recognized, though many pathogenetic ways of their toxicity still remain to be elucidated. Administration of trastuzumab is also clearly associated with cardiotoxicity, however, depression of left ventricular ejection fraction (LVEF) caused by this agent (unlike anthacyclines) seems to be fully reversible. For monitoring cardiotoxicity we use several methods--biochemical examination, use of X-ray, radionuclides or ultrasound. The most commonly used method to identify patients with heart damage is echocardiography with clinical examination. When a cardiac damage (mostly congestive heart failure with low LVEF) occures, following treatment depends on clinical symptoms and LVEF. These patients are then treated according to common internal medecine recommendations. Several cardioprotective agents have been tested, among these dexarazoxane seems do show significant cardioprotective activity. Also liposomal encapsulation of anthacyclines may reduce heart damage, especially early cardiotoxicity. Cardiotoxicity of cytostatic agents is a very serious side effect of anti-cancer therapy, which may affect survival more than the malignancy itself. Therefore a concentrated effort should be expended to prevent cardiac damage or at least to its early identification and prompt treatment.
A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

Sachin M. Hiradeve,Vaibhav P. Uplanchiwar,Namrata Mane,Gayatri Katole,Sanjana N. Gaikwad,Mayuri N. Deshmukh,Swati G. Gaikwad,Priya V. Nikam,Abhinav Bais,Vijendra Fulzele,Trupti S. Bobade,Mohd. Hashim Mansoori

DOI: https://doi.org/10.9734/jpri/2022/v34i7b35468

2022-02-03

Journal of Pharmaceutical Research International

Abstract:Doxorubicin has become one of the most effective chemotherapeutic agents, but its use was complicated by the development of heart failure. Proposed mechanisms for its antitumor effects included intercalation into DNA that caused the prevention of micro molecule synthesis, DNA cross-linkage and binding, DNA damage due to topoisomerase 2b suppression, reactive oxygen species production, and induction of apoptosis. Several drugs such as ACE inhibitors or the angiotensin receptor blockers, beta-blockers and the CHF therapy are used for the treatment processes. The present brief review of the literature, focuses on literature based on the mechanism of anthracycline-induced cardiotoxicity.
Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

Wei Huang,Rong Xu,Bin Zhou,Chao Lin,Yingkun Guo,Huayan Xu,Xia Guo

DOI: https://doi.org/10.3389/fcvm.2022.912329

2022-06-10

Abstract:The development of various antitumor drugs has significantly improved the survival of patients with cancer. Many first-line chemotherapy drugs are cytotoxic and the cardiotoxicity is one of the most significant effects that could leads to poor prognosis and decreased survival rate. Cancer treatment include traditional anthracycline drugs, as well as some new targeted drugs such as trastuzumab and ICIs. These drugs may directly or indirectly cause cardiovascular injury through different mechanisms, and lead to increasing the risk of cardiovascular disease or accelerating the development of cardiovascular disease. Cardiotoxicity is clinically manifested by arrhythmia, decreased cardiac function, or even sudden death. The cardiotoxicity caused by traditional chemotherapy drugs such as anthracyclines are significantly known. The cardiotoxicity of some new antitumor drugs such like immune checkpoint inhibitors (ICIs) is also relatively clear and requiring further observation and verification. This review is focused on major three drugs with relatively high incidence of cardiotoxicity and poor prognosis and intended to provide an update on the clinical complications and outcomes of these drugs, and we innovatively summarize the monitoring status of survivors using these drugs and discuss the biomarkers and non-invasive imaging features to identify early cardiotoxicity. Finally, we summarize the prevention that decreasing antitumor drugs-induced cardiotoxicity.
Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Chunping Liu,Huiqi Chen,Sien Guo,Qiaojing Liu,Zhijun Chen,Haiding Huang,Qi Zhao,Longmei Li,Huan Cen,Zebo Jiang,Qiyuan Luo,Xiaoling Chen,Jiaxiong Zhao,Wensheng Chen,Phillip C Yang,Lei Wang,Phillip C. Yang

DOI: https://doi.org/10.1016/j.biopha.2023.115373

2023-08-30

Abstract:With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to 90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting the survival of patients with breast cancer. Anthracyclines, such as doxorubicin, are still some of the most effective chemotherapeutic agents, but their resulting cardiotoxicity is generally considered to be progressive and irreversible. In addition to anthracyclines, platinum- and alkyl-based antitumor drugs also demonstrate certain cardiotoxic effects. Targeted drugs have always been considered a relatively safe option. However, in recent years, some random clinical trials have observed the occurrence of subclinical cardiotoxicity in targeted antitumor drug users, which may be related to the effects of targeted drugs on the angiotensin converting enzyme, angiotensin receptor and β receptor. The use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and beta-blockers may prevent clinical cardiotoxicity. This article reviews the toxicity and mechanisms of current clinical anti-breast cancer drugs and proposes strategies for preventing cardiovascular toxicity to provide recommendations for the clinical prevention and treatment of chemotherapy-related cardiomyopathy.

pharmacology & pharmacy,medicine, research & experimental
Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights

Xuwen Lin,Xidong Ma,Sheng Zhao,Jie Yao,Leng Han,Ying Jing,Xinying Xue

DOI: https://doi.org/10.1016/j.trecan.2024.07.004

IF: 19.161

2024-10-09

Trends in Cancer

Abstract:The evolution of antitumor therapies has significantly improved cancer prognosis but has concurrently resulted in cardiovascular toxicities. Understanding the biological mechanisms behind these toxicities is crucial for effective management. Immunotherapy-related cardiovascular toxicities are primarily mediated by immune cells and secreted cytokines. Chemotherapy may cause cardiovascular damage through autophagy disruption and mitochondrial dysfunction. Targeted therapies can induce toxicity through endothelin-1 (ET-1) production and cardiac signaling disruption. Radiotherapy may lead to cardiomyopathy and myocardial fibrosis by affecting endothelial cells, triggering inflammatory responses and accelerating atherosclerosis. This review provides insights into these mechanisms and strategies, aiming to enhance the clinical prevention and treatment of cardiovascular toxicities.

oncology
Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review

Tingting Yan,Hailong Yu,Tai Li,Yanhong Dong

DOI: https://doi.org/10.1016/j.hlc.2023.12.006

2024-01-01

Abstract:AIM: With the advancement of anti-cancer medicine, cardiovascular toxicities due to cancer therapies are common in oncology patients, resulting in increased mortality and economic burden. Cardiovascular toxicities caused by cancer therapies include different severities of cardiomyopathy, arrhythmia, myocardial ischaemia, hypertension, and thrombosis, which may lead to left ventricular dysfunction and heart failure. This scoping review aimed to summarise the mechanisms of cardiovascular toxicities following various anti-cancer treatments and potential predictive biomarkers for early detection.METHODS: PubMed, Cochrane, Embase, Web of Science, Scopus, and CINAHL databases were searched for original studies written in English related to the mechanisms of cardiovascular toxicity induced by anti-cancer therapies, including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and relevant biomarkers. The search and title/abstract screening were conducted independently by two reviewers, and the final analysed full texts achieved the consensus of the two reviewers.RESULTS: A total of 240 studies were identified based on their titles and abstracts. In total, 107 full-text articles were included in the analysis. Cardiomyocyte and endothelial cell apoptosis caused by oxidative stress injury, activation of cell apoptosis, blocking of normal cardiovascular protection signalling pathways, overactivation of immune cells, and myocardial remodelling were the main mechanisms. Promising biomarkers for anti-cancer therapies related to cardiovascular toxicity included placental growth factor, microRNAs, galectin-3, and myeloperoxidase for the early detection of cardiovascular toxicity.CONCLUSION: Understanding the mechanisms of cardiovascular toxicity following various anti-cancer treatments could provide implications for future personalised treatment methods to protect cardiovascular function. Furthermore, specific early sensitive and stable biomarkers of cardiovascular system damage need to be identified to predict reversible damage to the cardiovascular system and improve the effects of anti-cancer agents.

cardiac & cardiovascular systems
Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Ziyu Kuang,Yuansha Ge,Luchang Cao,Xinmiao Wang,Kexin Liu,Jiaxi Wang,Xiaojuan Zhu,Min Wu,Jie Li

DOI: https://doi.org/10.1007/s11864-024-01238-9

Abstract:Anthracycline (ANT)-induced cardiotoxicity (AIC) is a particularly prominent form of cancer therapy-related cardiovascular toxicity leading to the limitations of ANTs in clinical practice. Even though AIC has drawn particular attention, the best way to treat it is remaining unclear. Updates to AIC therapy have been made possible by recent developments in research on the underlying processes of AIC. We review the current molecular pathways leading to AIC: 1) oxidative stress (OS) including enzymatic-induced and other mechanisms; 2) topoisomerase; 3) inflammatory response; 4) cardiac progenitor cell damage; 5) epigenetic changes; 6) renin-angiotensin-aldosterone system (RAAS) dysregulation. And we systematically discuss current prevention and treatment strategies and novel pathogenesis-based therapies for AIC: 1) dose reduction and change; 2) altering drug delivery methods; 3) antioxidants, dexrezosen, statina, RAAS inhibitors, and hypoglycemic drugs; 4) miRNA, natural phytochemicals, mesenchymal stem cells, and cardiac progenitor cells. We also offer a fresh perspective on the management of AIC by outlining the current dilemmas and challenges associated with its prevention and treatment.
Role of mitochondria in doxorubicin-mediated cardiotoxicity: From molecular mechanisms to therapeutic strategies

Tianen Wang,Guoli Xing,Tong Fu,Yanchun Ma,Qi Wang,Shuxiang Zhang,Xing Chang,Ying Tong

DOI: https://doi.org/10.1016/j.cstres.2024.03.003

Abstract:This comprehensive review delves into the pivotal role of mitochondria in doxorubicin-induced cardiotoxicity, a significant complication limiting the clinical use of this potent anthracycline chemotherapeutic agent. Doxorubicin, while effective against various malignancies, is associated with dose-dependent cardiotoxicity, potentially leading to irreversible cardiac damage. The review meticulously dissects the molecular mechanisms underpinning this cardiotoxicity, particularly focusing on mitochondrial dysfunction, a central player in this adverse effect. Central to the discussion is the concept of mitochondrial quality control, including mitochondrial dynamics (fusion/fission balance) and mitophagy. The review presents evidence linking aberrations in these processes to cardiotoxicity in doxorubicin-treated patients. It elucidates how doxorubicin disrupts mitochondrial dynamics, leading to an imbalance between mitochondrial fission and fusion, and impairs mitophagy, culminating in the accumulation of dysfunctional mitochondria and subsequent cardiac cell damage. Furthermore, the review explores emerging therapeutic strategies targeting mitochondrial dysfunction. It highlights the potential of modulating mitochondrial dynamics and enhancing mitophagy to mitigate doxorubicin-induced cardiac damage. These strategies include pharmacological interventions with mitochondrial fission inhibitors, fusion promoters, and agents that modulate mitophagy. The review underscores the promising results from preclinical studies while advocating for more extensive clinical trials to validate these approaches in human patients. In conclusion, this review offers valuable insights into the intricate relationship between mitochondrial dysfunction and doxorubicin-mediated cardiotoxicity. It underscores the need for continued research into targeted mitochondrial therapies as a means to improve the cardiac safety profile of doxorubicin, thereby enhancing the overall treatment outcomes for cancer patients.
Further evidence for GABA-ergic mechanisms in the action of benzodiazepines.

V. V. Zakusov,R. Ostrovskaya,S. N. Kozhechkin,V. Markovich,G. Molodavkin,T. Voronina

1977-10-01

Abstract:Drugs of the benzodiazepine series (clonazepam, lorazepam, diazepam and medazepam) increase the inhibitory processes in the cerebral cortex as it has been shown by means of the recovery cycles of the intracortical response. There is a correlation between the effect on the recovery cycles and their protective action against convulsions induced by GABA deficit. Diazepam enhances the inhibitory effect of GABA applied iontophoretically to rabbit sensorymotor cortex neurons. The drug GABA-ergic effect seems to be specific since it fails to modify the effects of other putative neurotransmitters (glutamate, glycine, acetylcholine). The alteration of rat conflict situation behaviour under diazepam has been eliminated due to the blockade of GABA-receptors by gicuculline and the decrease of the GABA level by thiosemicarbazide. It is inferred that the main effects of benzodiazepines are mediated by GABA and suggested that these agents increase the sensitivity of postsynaptic GABA-ergic receptors.
An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Sicong Xie,Yuwei Sun,Xuan Zhao,Yiqun Xiao,Fei Zhou,Liang Lin,Wei Wang,Bin Lin,Zun Wang,Zixuan Fang,Lei Wang,Yang Zhang

DOI: https://doi.org/10.3389/fphar.2024.1406247

IF: 5.6

2024-06-26

Frontiers in Pharmacology

Abstract:Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin, which are widely used to treat a variety of malignant tumors, such as breast cancer, gastrointestinal tumors, lymphoma, etc. With the accumulation of anthracycline drugs in the body, they can induce serious heart damage, limiting their clinical application. The mechanism by which anthracycline drugs cause cardiotoxicity is not yet clear. This review provides an overview of the different types of cardiac damage induced by anthracycline-class drugs and delves into the molecular mechanisms behind these injuries. Cardiac damage primarily involves alterations in myocardial cell function and pathological cell death, encompassing mitochondrial dysfunction, topoisomerase inhibition, disruptions in iron ion metabolism, myofibril degradation, and oxidative stress. Mechanisms of uptake and transport in anthracycline-induced cardiotoxicity are emphasized, as well as the role and breakthroughs of iPSC in cardiotoxicity studies. Selected novel cardioprotective therapies and mechanisms are updated. Mechanisms and protective strategies associated with anthracycline cardiotoxicity in animal experiments are examined, and the definition of drug damage in humans and animal models is discussed. Understanding these molecular mechanisms is of paramount importance in mitigating anthracycline-induced cardiac toxicity and guiding the development of safer approaches in cancer treatment.

pharmacology & pharmacy
Focus on Molecular Mechanisms to Improve Therapeutic Management

Serena Barachini,Gabriele Buda,Iacopo Petrini

DOI: https://doi.org/10.3390/jcm13061574

IF: 3.9

2024-03-10

Journal of Clinical Medicine

Abstract:In recent years, advancements in the treatment of hematologic neoplasms have led to more effective and less toxic therapeutic schemes, resulting in prolonged patient life expectancy. However, the success of these treatments has also brought about an increased prevalence of cardiovascular adverse events, becoming a significant concern for the growing population of cancer survivors. Antineoplastic therapies, targeting both tumor and organ vessels, contribute to vascular toxicity, influenced by genetic factors and pre-existing vascular diseases. Chemotherapeutic agents and targeted treatments can induce cardiovascular toxicity by affecting endothelial cells and cardiomyocytes through various mechanisms, including hypoxia, vasculature abnormalities, and direct effects on cardiomyocytes. Cardiovascular adverse events encompass a wide range, from cardiac dysfunction to an elevated risk of arrhythmias. While early cardiac events are well-described in clinical trials, delayed toxicities are gaining relevance due to prolonged patient survival. The review focuses on the cardiac and vascular toxicity of antineoplastic drugs in hematological disorders, providing insights into the molecular physiopathology of cancer therapy-associated cardiotoxicity. Understanding how these drugs interact with the heart and blood vessels is essential for predicting, detecting, and managing chemotherapy-related heart issues.

medicine, general & internal
Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies

Cho-Won Kim,Kyung-Chul Choi

DOI: https://doi.org/10.1016/j.lfs.2021.119607

IF: 6.78

2021-07-01

Life Sciences

Abstract:Mitochondria are organelles that play a pivotal role in the production of energy in cells, and vital to the maintenance of cellular homeostasis due to the regulation of many biochemical processes. The heart contains a lot of mitochondria because those muscles require a lot of energy to keep supplying blood through the circulatory system, implying that the energy generated from mitochondria is highly dependent. Thus, cardiomyocytes are sensitive to mitochondrial dysfunction and are likely to be targeted by mitochondrial toxic drugs. It has been reported that some anticancer drugs caused unwanted toxicity to mitochondria. Mitochondrial dysfunction is related to aging and the onset of many diseases, such as obesity, diabetes, cancer, cardiovascular and neurodegenerative diseases. Mitochondrial toxic mechanisms can be mainly explained concerning reactive oxygen species (ROS)/redox status, calcium homeostasis, and endoplasmic reticulum stress (ER) stress signaling. The toxic mechanisms of many anticancer drugs have been revealed, but more studying and understanding of the mechanisms of drug-induced mitochondrial toxicity is required to develop mitochondrial toxicity screening system as well as novel cardioprotective strategies for the prevention of cardiac disorders of drugs. This review focuses on the cardiac mitochondrial toxicity of commonly used anticancer drugs, i.e., doxorubicin, mitoxantrone, cisplatin, arsenic trioxide, and cyclophosphamide, and their possible chemopreventive agents that can prevent or alleviate cardiac mitochondrial toxicity.

pharmacology & pharmacy,medicine, research & experimental
Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer

Amit Manhas,Dipti Tripathi,Dilip Thomas,Nazish Sayed

DOI: https://doi.org/10.1007/s11886-024-02099-2

Abstract:Purpose of review: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling. Recent findings: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.
Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review

Luai Madanat,Ruby Gupta,Paul Weber,Navneet Kumar,Rohit Chandra,Hycienth Ahaneku,Yatharth Bansal,Joseph Anderson,Abhay Bilolikar,Ishmael Jaiyesimi

DOI: https://doi.org/10.2174/1573403X18666220531094800

Abstract:Cardiotoxicity from chemotherapy regimens has been long reported. However, the understanding of cardiac side effects of biological therapies is rapidly evolving. With cancer patients achieving higher life expectancy due to the use of personalized medicine and novel targeted anticancer agents, the occurrence of cardiotoxicity is becoming more significant. Novel biological therapies include anti-HER2 antibodies, tyrosine kinase inhibitors, bruton kinase inhibitors, antivascular endothelial growth factors, proteasome inhibitors, immunomodulator drugs, and immune checkpoint inhibitors. Potential cardiovascular toxicities linked to these anticancer agents include hypertension, arrhythmias, QT prolongation, myocardial ischemia and infarction, left ventricular dysfunction, congestive heart failure, and thromboembolism. Cardiac biomarkers, electrocardiography, echocardiography and magnetic resonance imaging are common diagnostic modalities used for early detection of these complications and timely intervention. This review discusses the various types of cardiotoxicities caused by novel anticancer biologic agents, their molecular and pathophysiological mechanisms, risk factors, and diagnostic and management strategies that can be used to prevent, minimize, and treat them.
Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

Anna Stansfeld,Utsav Radia,Caitriona Goggin,Preethika Mahalingam,Charlotte Benson,Andrea Napolitano,Robin L Jones,Stuart D Rosen,Vasilios Karavasilis

DOI: https://doi.org/10.1080/14656566.2022.2124107

2022-09-15

Expert Opinion on Pharmacotherapy

Abstract:Anthracycline chemotherapeutic agents are widely used in the treatment of hematological and solid tumors, working principally through DNA intercalation and topoisomerase II inhibition. However, they are also well known to have cardiotoxic sequelae, commonly denoted as a reduction in ejection fraction. Drug-associated cardiotoxicity remains a significant limiting factor in the use of anthracyclines. In this review, we explore the potential mechanisms of anthracycline-associated cardiotoxicity, identifying high-risk cohorts and approaches to cardiovascular monitoring. The mechanisms through which cardiotoxicity occurs are complex and diverse, ultimately leading to increased oxidative stress, mitochondrial dysfunction, and subsequent cellular apoptosis. Many of the cardiotoxic effects of anthracyclines exhibit a dose-dependent cumulative relationship and are more apparent in patients with previously existing cardiovascular risk factors. Long-term cardiovascular monitoring and optimization of risk factors, prior to commencing treatment as well as beyond the time of treatment, is therefore essential. We discuss some of the pharmacological strategies proposed to mitigate anthracycline-associated cardiotoxicity as well as prevention strategies to reduce the burden of coexisting cardiovascular risk factors. We highlight methods of early detection of patient cohorts who are at increased risk of developing anthracycline-associated cardiotoxicity and identify potential avenues for further research.

pharmacology & pharmacy
WASP-NET: Recent advances in fast EM CAD and optimization of waveguide components, feeds and aperture antennas

F. Arndt

DOI: https://doi.org/10.1109/APS.2012.6348420

2012-07-08

Abstract:WASP-NET's advanced multi-solver hybrid domain (de)composition technique, which is uniquely based on six solvers - mode-matching (MM) / finite-element (FE) / method-of-moment (MoM) / finite-difference (FD) / finite-element boundary-integral (FE-BI) / physical theory of diffraction (PTD) -, fully utilizes the efficiency and flexibility advantages of the involved methods. The CAD tool's recent advances include a graphical 3D structure editor for arbitrary user-defined structures parametrized by variables, 3D structure import via standard data formats, and the inclusion of efficient MoM techniques for, e.g., radar cross-section (RCS) investigations, fast optimizations of large antenna arrays, and the inclusion of lossy dielectrics and tensor materials. The high calculation speed and 3D flexibility will be demonstrated at typical examples that are relevant for the antenna engineer, e.g., arbitrarily shaped ortho-mode-transducers (OMTs), shaped reflector antennas with layered, lossy radomes, and slot arrays.
Non-coding RNAs in cancer therapy-induced cardiotoxicity: Mechanisms, biomarkers, and treatments

Wanli Sun,Juping Xu,Li Wang,Yuchen Jiang,Jingrun Cui,Xin Su,Fan Yang,Li Tian,Zeyu Si,Yanwei Xing

DOI: https://doi.org/10.3389/fcvm.2022.946137

IF: 3.6

2022-01-01

Frontiers in Cardiovascular Medicine

Abstract:As a result of ongoing breakthroughs in cancer therapy, cancer patients' survival rates have grown considerably. However, cardiotoxicity has emerged as the most dangerous toxic side effect of cancer treatment, negatively impacting cancer patients' prognosis. In recent years, the link between non-coding RNAs (ncRNAs) and cancer therapy-induced cardiotoxicity has received much attention and investigation. NcRNAs are non-protein-coding RNAs that impact gene expression post-transcriptionally. They include microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). In several cancer treatments, such as chemotherapy, radiotherapy, and targeted therapy-induced cardiotoxicity, ncRNAs play a significant role in the onset and progression of cardiotoxicity. This review focuses on the mechanisms of ncRNAs in cancer therapy-induced cardiotoxicity, including apoptosis, mitochondrial damage, oxidative stress, DNA damage, inflammation, autophagy, aging, calcium homeostasis, vascular homeostasis, and fibrosis. In addition, this review explores potential ncRNAs-based biomarkers and therapeutic strategies, which may help to convert ncRNAs research into clinical practice in the future for early detection and improvement of cancer therapy-induced cardiotoxicity.
Screening of renal artery stenosis: assessment with magnetic resonance angiography at 1.0 T.

J. Laissy,M. Benyounes,O. Limot,A. Cinqualbre,H. Benamer,S. Kenouch,M. Henry-Feugeas,B. Falise,S. Chillon,P. Valere,E. Schouman‐Claeys

DOI: https://doi.org/10.1016/S0730-725X(96)00097-5

IF: 3.13

Magnetic Resonance Imaging

Abstract:

In vitro bone lipid synthesis in air and nitrogen.

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

[Cardiotoxicity of drugs used in oncology]

A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights

Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Role of mitochondria in doxorubicin-mediated cardiotoxicity: From molecular mechanisms to therapeutic strategies

Further evidence for GABA-ergic mechanisms in the action of benzodiazepines.

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Focus on Molecular Mechanisms to Improve Therapeutic Management

Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies

Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer

Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

WASP-NET: Recent advances in fast EM CAD and optimization of waveguide components, feeds and aperture antennas

Non-coding RNAs in cancer therapy-induced cardiotoxicity: Mechanisms, biomarkers, and treatments

Screening of renal artery stenosis: assessment with magnetic resonance angiography at 1.0 T.